drugset / Trial / NCT03161379
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
Phase 2
Completed
31 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation Therapy (SBRT) in patients with pancreatic cancer.
Timeline
- Start
- 2018-02-02
- Primary completion
- 2024-02-20
- Completion
- 2024-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GVAX Pancreas Vaccine | Vaccine | — | — |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | — |
| Background | Cyclophosphamide | Other / unclassified | 200 mg/m2 | — |